论文部分内容阅读
最近美国研究出一种重组的可溶性CD4蛋白质,用于艾滋病的治疗。通常引起艾滋病的HIV吸附到细胞CD4受体后,进入细胞内(仅仅是淋巴细胞),利用宿主的细胞器进行复制,导致细胞死亡。静注相对大量的游离重组CD4蛋白,可提供细胞受体CD4替代物,这样可延迟或阻止艾滋病的发生和发展。美国食品药物管理局已批准将此方法用于治疗HIV感染者的临床研究。
Recently, the United States has developed a recombinant soluble CD4 protein for the treatment of AIDS. HIV, which usually causes AIDS, adsorbs to the cell’s CD4 receptor, enters the cell (only lymphocytes) and makes use of the host’s organelles for replication, resulting in cell death. A relatively large amount of free recombinant CD4 protein intravenously can provide CD4 receptor for cell receptors, which can delay or prevent the occurrence and development of AIDS. The U.S. Food and Drug Administration has approved clinical trials of this method for the treatment of HIV-infected individuals.